Search

Your search keyword '"Picarelli, S"' showing total 12 results
Start Over Author "Picarelli, S" Search Limiters Available in Library Collection
12 results on '"Picarelli, S"'

4. P529Efficacy and safety of S-ICD implantation without use of defibrillation threshold testing: a retrospective multicentric observational study

Author

Ricciardi, D, primary, Picarelli, F, additional, Forleo, G B, additional, Di Belardino, N, additional, Bisignani, A, additional, Bisignani, G, additional, Santini, L, additional, Lavalle, C, additional, Pignalberi, C, additional, Picarelli, S, additional, Aurino, L, additional, Creta, A, additional, Calabrese, V, additional, Gioia, F A, additional, and Grigioni, F, additional

Published
2020
Full Text
View/download PDF

5. REPRODUCTIVE ENDOCRINOLOGY

Author

Karasu, Y., primary, Dilbaz, B., additional, Demir, B., additional, Dilbaz, S., additional, Secilmis Kerimoglu, O., additional, Ercan, C. M., additional, Keskin, U., additional, Korkmaz, C., additional, Duru, N. K., additional, Ergun, A., additional, de Zuniga, I., additional, Horton, M., additional, Oubina, A., additional, Scotti, L., additional, Abramovich, D., additional, Pascuali, N., additional, Tesone, M., additional, Parborell, F., additional, Bouzas, N., additional, Yang, X. H., additional, Chen, S. L., additional, Chen, X., additional, Ye, D. S., additional, Zheng, H. Y., additional, Nyboe Andersen, A., additional, Lauritsen, M. P., additional, Thuesen, L. L., additional, Khodadadi, M., additional, Shivabasavaiah, S., additional, Mozafari, R., additional, Ansari, Z., additional, Hamdine, O., additional, Broekmans, F., additional, Eijkemans, M. J. C., additional, Cohlen, B. J., additional, Verhoeff, A., additional, van Dop, P. A., additional, Bernardus, R. E., additional, Lambalk, C. B., additional, Oosterhuis, G. J. E., additional, Holleboom, C., additional, van den Dool-Maasland, G. C., additional, Verburg, H. J., additional, van der Heijden, P. F. M., additional, Blankhart, A., additional, Fauser, B. C. J. M., additional, Laven, J. S. E., additional, Macklon, N. S., additional, Agudo, D., additional, Lopez, C., additional, Alonso, M., additional, Huguet, E., additional, Bronet, F., additional, Garcia-Velasco, J. A., additional, Requena, A., additional, Gonzalez Comadran, M., additional, Checa, M. A., additional, Duran, M., additional, Fabregues, F., additional, Carreras, R., additional, Ersahin, A., additional, Kahraman, S., additional, Kavrut, M., additional, Gorgen, B., additional, Acet, M., additional, Dokuzeylul, N., additional, Aybar, F., additional, Lim, S. Y., additional, Park, J. C., additional, Bae, J. G., additional, Kim, J. I., additional, Rhee, J. H., additional, Mahran, A., additional, Abdelmeged, A., additional, El-Adawy, A., additional, Eissa, M., additional, Darne, J., additional, Shaw, R. W., additional, Amer, S. A., additional, Dai, A., additional, Yan, G., additional, He, Q., additional, Hu, Y., additional, Sun, H., additional, Ferrero, H., additional, Gomez, R., additional, Garcia-Pascual, C. M., additional, Simon, C., additional, Gaytan, F., additional, Pellicer, A., additional, Garcia Pascual, C. M., additional, Zimmermann, R. C., additional, Madani, T., additional, Mohammadi Yeganeh, L., additional, Khodabakhshi, S. H., additional, Akhoond, M. R., additional, Hasani, F., additional, Monzo, C., additional, Haouzi, D., additional, Assou, S., additional, Dechaud, H., additional, Hamamah, S., additional, Amer, S., additional, Mahran, M., additional, Shaw, R., additional, Lan, V., additional, Nhu, G., additional, Tuong, H., additional, Mahmoud Youssef, M. A., additional, Aboulfoutouh, I., additional, Al-inany, H., additional, Van Der Veen, F., additional, Van Wely, M., additional, Zhang, Q., additional, Fang, T., additional, Wu, S., additional, Zhang, L., additional, Wang, B., additional, Li, X., additional, Ding, L., additional, Day, A., additional, Fulford, B., additional, Boivin, J., additional, Alanbay, I., additional, Sakinci, M., additional, Coksuer, H., additional, Ozturk, M., additional, Tapan, S., additional, Chung, C. K., additional, Chung, Y., additional, Seo, S., additional, Aksoy, S., additional, Yakin, K., additional, Caliskan, S., additional, Salar, Z., additional, Ata, B., additional, Urman, B., additional, Devroey, P., additional, Arce, J. C., additional, Harrison, K., additional, Irving, J., additional, Osborn, J., additional, Harrison, M., additional, Fusi, F., additional, Arnoldi, M., additional, Cappato, M., additional, Galbignani, E., additional, Galimberti, A., additional, Zanga, L., additional, Frigerio, L., additional, Taghavi, S. A., additional, Ashrafi, M., additional, Karimian, L., additional, Mehdizadeh, M., additional, Joghataie, M., additional, Aflatoonian, R., additional, Xu, B., additional, Cui, Y. G., additional, Gao, L. L., additional, Diao, F. Y., additional, Li, M., additional, Liu, X. Q., additional, Liu, J. Y., additional, Jiang, F., additional, Jee, B. C., additional, Yi, G., additional, Kim, J. Y., additional, Suh, C. S., additional, Kim, S. H., additional, Liu, S., additional, Cai, L. B., additional, Liu, J. J., additional, Ma, X., additional, Geenen, E., additional, Bots, R. S. G. M., additional, Smeenk, J. M. J., additional, Chang, E., additional, Lee, W., additional, Seok, H., additional, Kim, Y., additional, Han, J., additional, Yoon, T., additional, Lazaros, L., additional, Xita, N., additional, Zikopoulos, K., additional, Makrydimas, G., additional, Kaponis, A., additional, Sofikitis, N., additional, Stefos, T., additional, Hatzi, E., additional, Georgiou, I., additional, Atilgan, R., additional, Kumbak, B., additional, Sahin, L., additional, Ozkan, Z. S., additional, Simsek, M., additional, Sapmaz, E., additional, Karacan, M., additional, Alwaeely, F. A., additional, Cebi, Z., additional, Berberoglugil, M., additional, Ulug, M., additional, Camlibel, T., additional, Yelke, H., additional, Kamalak, Z., additional, Carlioglu, A., additional, Akdeniz, D., additional, Uysal, S., additional, Inegol Gumus, I., additional, Ozturk Turhan, N., additional, Regan, S., additional, Yovich, J., additional, Stanger, J., additional, Almahbobi, G., additional, Kara, M., additional, Aydin, T., additional, Turktekin, N., additional, Youssef, M., additional, Al-Inany, H., additional, van der Veen, F., additional, van Wely, M., additional, Hart, R., additional, Doherty, D., additional, Frederiksen, H., additional, Keelan, J., additional, Pennell, C., additional, Newnham, J., additional, Skakkebaek, N., additional, Main, K., additional, Salem, H. T., additional, Ismail, A. a., additional, Viola, M., additional, Siebert, T. I., additional, Steyn, D. W., additional, Kruger, T. F., additional, Robin, G., additional, Dewailly, D., additional, Thomas, P., additional, Leroy, M., additional, Lefebvre, C., additional, soudan, B., additional, Pigny, P., additional, Decanter, C., additional, ElPrince, M., additional, Wang, F., additional, Zhu, Y., additional, Huang, H., additional, Valdez Morales, F., additional, Vital Reyes, V., additional, Mendoza Rodriguez, A., additional, Gamboa Dominguez, A., additional, Cerbon, M., additional, Aizpurua, J., additional, Ramos, B., additional, Luehr, B., additional, Moragues, I., additional, Rogel, S., additional, Cil, A. P., additional, Guler, Z. B., additional, Kisa, U., additional, Albu, A., additional, Radian, S., additional, Grigorescu, F., additional, Albu, D., additional, Fica, S., additional, Al Boghdady, L., additional, Ghanem, M. E., additional, Hassan, M., additional, Helal, A. S., additional, Ozdogan, S., additional, Ozdegirmenci, O., additional, Cinar, O., additional, Goktolga, U., additional, Seeber, B., additional, Tsybulyak, I., additional, Bottcher, B., additional, Grubinger, T., additional, Czech, T., additional, Wildt, L., additional, Wojcik, J., additional, Howles, C. M., additional, Destenaves, B., additional, Arriagada, P., additional, Tavmergen, E., additional, Sahin, G., additional, Akdogan, A., additional, Levi, R., additional, Goker, E. N. T., additional, Loft, A., additional, Smitz, J., additional, Ricciardi, L., additional, Di Florio, C., additional, Busacca, M., additional, Gagliano, D., additional, Immediata, V., additional, Selvaggi, L., additional, Romualdi, D., additional, Guido, M., additional, Bouhanna, P., additional, Salama, S., additional, Kamoud, Z., additional, Torre, A., additional, Paillusson, B., additional, Fuchs, F., additional, Bailly, M., additional, Wainer, R., additional, Tagliaferri, V., additional, Tartaglia, C., additional, Cirella, E., additional, Aflatoonian, A., additional, Eftekhar, M., additional, Mohammadian, F., additional, Yousefnejad, F., additional, De Cicco, S., additional, Campagna, G., additional, Depalo, R., additional, Lippolis, C., additional, Vacca, M., additional, Nardelli, C., additional, Cavallini, A., additional, Panic, T., additional, Mitulovic, G., additional, Franz, M., additional, Sator, K., additional, Tschugguel, W., additional, Pietrowski, D., additional, Hildebrandt, T., additional, Cupisti, S., additional, Giltay, E. J., additional, Gooren, L. J., additional, Oppelt, P. G., additional, Hackl, J., additional, Reissmann, C., additional, Schulze, C., additional, Heusinger, K., additional, Attig, M., additional, Hoffmann, I., additional, Beckmann, M. W., additional, Dittrich, R., additional, Mueller, A., additional, Sharma, S., additional, Singh, S., additional, Chakravarty, A., additional, Sarkar, A., additional, Rajani, S., additional, Chakravarty, B. N., additional, Ozturk, E., additional, Isikoglu, S., additional, Kul, S., additional, Hillensjo, T., additional, Witjes, H., additional, Elbers, J., additional, Mannaerts, B., additional, Gordon, K., additional, Krasnopolskaya, K., additional, Galaktionova, A., additional, Gorskaya, O., additional, Kabanova, D., additional, Venturella, R., additional, Morelli, M., additional, Mocciaro, R., additional, Capasso, S., additional, Cappiello, F., additional, Zullo, F., additional, Monterde, M., additional, Marzal, A., additional, Vega, O., additional, Rubio-Rubio, J. M., additional, Diaz-Garcia, C., additional, Kolibianakis, E., additional, Griesinger, G., additional, Yding Andersen, C., additional, Ocal, P., additional, Guralp, O., additional, Aydogan, B., additional, Irez, T., additional, Cetin, M., additional, Senol, H., additional, Erol, N., additional, Rombauts, L., additional, Van Kuijk, J., additional, Montagut, J., additional, Nogueira, D., additional, Porcu, G., additional, Chomier, M., additional, Giorgetti, C., additional, Nicollet, B., additional, Degoy, J., additional, Lehert, P., additional, Alviggi, C., additional, De Rosa, P., additional, Vallone, R., additional, Picarelli, S., additional, Coppola, M., additional, Conforti, A., additional, Strina, I., additional, Di Carlo, C., additional, De Placido, G., additional, Haeberle, L., additional, Demirtas, O., additional, Fatemi, H., additional, Shapiro, B. S., additional, Mannaerts, B. M., additional, Chimote, M. N., additional, Mehta, B. N., additional, Chimote, N. N., additional, Nath, N. M., additional, Chimote, N. M., additional, Karia, S., additional, Bonifacio, M., additional, Bowman, M., additional, McArthur, S., additional, Jung, J., additional, Cho, S., additional, Choi, Y., additional, Lee, B., additional, Lee, K. H., additional, Kim, C. H., additional, Kwon, S. K., additional, Kang, B. M., additional, Jung, K. S., additional, Basios, G., additional, Trakakis, E., additional, Hatziagelaki, E., additional, Vaggopoulos, V., additional, Tsiavou, A., additional, Panagopoulos, P., additional, Chrelias, C., additional, Kassanos, D., additional, Sarhan, A., additional, Elsamanoudy, A., additional, Harira, M., additional, Dogan, S., additional, Bozdag, G., additional, Esinler, I., additional, Polat, M., additional, and Yarali, H., additional

Published
2012
Full Text
View/download PDF

7. High progesterone levels during the luteal phase related to the use of an aromatase inhibitor in breast cancer patients

Author

Carlo Alviggi, Marci, R., Vallone, R., Conforti, A., Di Rella, F., Strina, I., Picarelli, S., Rosa, P., Laurentiis, M., Yding Andersen, C., Placido, G., Alviggi, C, Marci, R, Vallone, R, Conforti, A, Di Rella, F, Strina, I, Picarelli, S, De Rosa, P, De Laurentiis, M, Yding Andersen, C, and De Placido, G.

Subjects
Adult, Aromatase inhibitor, Breast cancer, Controlled ovarian stimulation, Fertility preservation, Letrozole, Pharmacology (medical), Aromatase Inhibitors, Socio-culturale, Breast Neoplasms, Luteal Phase, Triazoles, Chorionic Gonadotropin, Recombinant Proteins, Gonadotropin-Releasing Hormone, Ovulation Induction, Nitriles, Humans, Female, Follicle Stimulating Hormone, Progesterone
Abstract

To evaluate the hormonal profile in three breast cancer patients who underwent controlled ovarian stimulation in the presence of the aromatase inhibitor letrozole.In IVF University referral center, a case series of three breast cancer patients who underwent controlled ovarian stimulation (COS) with recombinant FSH and letrozole were investigated. Ovulation was induced with hCG (case No. 1) or with GnRH agonist (case No. 2-3). The primary outcome of our study was the detection of progesterone levels in the luteal phase.Very high progesterone values (mean 186.6 ± 43.6 ng/mL) during the luteal phase were recorded in all three cases.High progesterone levels can be related to the use of letrozole independently of the most commonly used trigger regimen. Although progesterone has long been considered a protective factor against breast cancer, several studies have demonstrated that progesterone could expand a transformation-sensitive stem cell population in the mammary glands. The estrogen negative feedback effect on the hypothalamus-pituitary axis and the disruption of steroid biosynthesis and could represent an intriguing reason behind this phenomenon. Our results highlight the need to evaluate further the increase in progesterone levels in the luteal phase in women with breast cancer undergoing COS with letrozole.

8. Perinatal and obstetric outcomes in singleton pregnancies following fresh versus cryopreserved blastocyst transfer: a meta-analysis

Author

Filippo Maria Ubaldi, Alberto Vaiarelli, Fulvio Zullo, Danilo Cimadomo, Roberta Venturella, Carlo Alviggi, Silvia Picarelli, Alessandro Conforti, Laura Rienzi, Luigi Carbone, Antonio La Marca, Conforti, A., Picarelli, S., Carbone, L., La Marca, A., Venturella, R., Vaiarelli, A., Cimadomo, D., Zullo, F., Rienzi, L., Ubaldi, F. M., and Alviggi, C.

Subjects
0301 basic medicine, medicine.medical_specialty, Fresh cycle, Cryopreserved cycle, 03 medical and health sciences, 0302 clinical medicine, ART, Blastocyst, Cryopreserved cycles, Fresh cycles, Perinatal outcome, Pregnancy, medicine, Humans, reproductive and urinary physiology, Cryopreservation, 030219 obstetrics & reproductive medicine, Singleton, Obstetrics, business.industry, Blastocyst Transfer, Infant, Newborn, Pregnancy Outcome, Obstetrics and Gynecology, Gestational age, Odds ratio, Infant, Low Birth Weight, Delivery, Obstetric, Confidence interval, Embryo transfer, 030104 developmental biology, medicine.anatomical_structure, Reproductive Medicine, Meta-analysis, embryonic structures, Female, business, Infant, Premature, Developmental Biology
Abstract

The transfer of cryopreserved blastocysts is increasing in IVF centres. However, little is known about the perinatal and obstetric outcomes of this procedure. In an attempt to further elucidate these issues, a systematic review and meta-analysis was conducted to compare cryopreserved transfer with fresh blastocyst embryo transfer. The results show that the risk of both preterm (odds ratio [OR] 0.89, 95% confidence interval [CI] 0.80–0.99, P = 0.04) and low birthweight births (OR 0.82, 95% CI 0.68–0.99, P = 0.04) was significantly lower after cryopreserved blastocyst transfer than after fresh blastocyst transfer. The rate of large for gestational age births was significantly higher (OR 1.68, 95% CI 1.55–1.82, P < 0.00001) and the rate of small for gestational age births significantly lower (OR 0.59, 95% CI 0.54–0.65, P < 0.00001) after cryopreserved blastocyst transfer. The transfer of cryopreserved blastocysts was associated with a significantly lower risk of placental abruption (OR 0.58, 95% CI 0.40–0.83, P = 0.003) but a significantly higher risk of Caesarean section (OR 1.21, 95% CI 1.01–1.43, P = 0.03). In conclusion, the perinatal and obstetric outcomes associated with the transfer of cryopreserved blastocysts differ from those associated with fresh blastocyst transfer.

Published
2021

9. Ivf during coronavirus pandemic: Who comes first? the poseidon viewpoint

Author

R. Di Girolamo, Cira Buonfantino, Luigi Carbone, P. De Rosa, Carlo Alviggi, Ida Strina, Alessandro Conforti, Silvia Picarelli, S. C. Esteves, Roberta Vallone, Picarelli, S., Conforti, A., Buonfantino, C., Vallone, R., De Rosa, P., Carbone, L., Di Girolamo, R., Strina, I., Esteves, S. C., and Alviggi, C.

Subjects
Ivf treatment, Infertility, 2019-20 coronavirus outbreak, medicine.medical_specialty, Medical staff, Coronavirus disease 2019 (COVID-19), business.industry, Risk of infection, Reproductive medicine, COVID-19, medicine.disease, Assisted reproductive technology, POSEIDON criteria, Viewpoint, In vitro fertilization, Pandemic, Medicine, business, Intensive care medicine
Abstract

COVID-19 is the world’s most massive epidemic known to date. In order to prevent hospital burdens, governments around the world have adopted restrictive containment mea-sures. Such measures have led to a temporary suspension of all non-urgent clinical procedures. With the reduction of con-tagions, in some country there is a slow and gradual restoration of clinical treatments including reproductive medicine. Even with all safety precautions, the risk of infection is real for infertility patients, medical staff, and the community, making it crucial to establish which infertile patients should be prioritized for treatment provision. Indeed, postponing treatments in infertile patients who show a strictly time-de-pendent reproductive prognosis, could definitely affect reproductive chances. In this sense, POSEIDON group propose the use of a specific algorithm that could help clinicians to most optimally manage who need immediate IVF treatment during COVID-19 pandemic.

Published
2020

10. In vitro expansion of human breast cancer epithelial and mesenchymal stromal cells: optimization of a coculture model for personalized therapy approaches

Author

Sabino De Placido, Giampaolo Tortora, Sara Corvigno, Silvia Picarelli, Agostina Nardone, Fortunato Ciardiello, Bianca Maria Veneziani, Vittoria Criniti, Gennaro Limite, Carla Cavaliere, Veneziani, BIANCA MARIA, Criniti, V, Cavaliere, C, Corvigno, S, Nardone, A, Picarelli, S, Tortora, Giampaolo, Ciardiello, F, Limite, G, DE PLACIDO, Sabino, Veneziani, Bm, Tortora, G, Ciardiello, Fortunato, and DE PLACIDO, S.

Subjects
Cancer Research, Stromal cell, medicine.drug_class, medicine.medical_treatment, Blotting, Western, Breast Neoplasms, Antibodies, Monoclonal, Humanized, Formestane, breast cancer cocultures aromatase inhibitors endocrine therapy epidermal growth factor receptor inhibitors, Targeted therapy, Mesoderm, Breast cancer, Aromatase, Coculture model, Cell Line, Tumor, Medicine, Humans, RNA, Messenger, DNA Primers, Cryopreservation, Aromatase inhibitor, biology, Base Sequence, business.industry, Aromatase Inhibitors, Reverse Transcriptase Polymerase Chain Reaction, Androstenedione, Cancer, Antibodies, Monoclonal, Epithelial Cells, Trastuzumab, medicine.disease, Coculture Techniques, epithelial cells, stromal cells, Oncology, Cancer cell, Immunology, biology.protein, Cancer research, Stromal Cells, business, medicine.drug
Abstract

Molecularly targeted, customized therapies are designed based on the molecular portraits of cancer tissue. The efficacy of targeted therapy in individual patients depends on the contribution of single individual cancer cells within the context of their microenvironment. We have developed an in vitro model of human mammary epithelial-stromal cocultures to answer specific clinical questions related to breast cancer, to provide a tool with which to identify a signature in each breast tumor, and to identify the metabolic molecular targets of therapy in an attempt to optimize the efficacy of targeted therapy in each patient. Fifty-five human breast cancer samples were obtained through surgery. Epithelial and stromal cells were isolated from tissue specimens by differential centrifugation, and cryopreserved. Western blot analysis and RT-PCR were used to identify the tissue-specific expression patterns of cancer cells. Dose-response curves were constructed for the aromatase inhibitor formestane and for herceptin, and a 3-(4,5-dimethylthiazol)-2,5-diphenyltetrazolium bromide assay was done for combined treatment. We collected and cryopreserved, for future use, viable living cells from 55 breast tumor specimens from which we derived short-term cocultures. The presence of cytokeratins and vimentin was evaluated in 20 samples, and pHER2/neu and aromatase were evaluated in 4 cocultures. Formestane and herceptin had a cumulative growth-inhibitory effect on cocultures expressing epidermal growth factor receptors and aromatase. The in vitro model of human mammary epithelial-stromal cocultures reported herein can be used to examine, and to store, a patient's tumor-derived, living cells that retain the characteristics of the mother-tissue and respond, in vitro, to therapy. [Mol Cancer Ther 2007;6(12):3091–100]

Published
2007

11. Association between intrafollicular concentration of benzene and outcome of controlled ovarian stimulation in IVF/ICSI cycles: a pilot study

Author

Carlo Alviggi, Ida Strina, Silvia Picarelli, R. Guadagni, Pasquale De Rosa, Antonio Acampora, Antonio Mollo, Roberta Vallone, Tiziana Pagano, Giuseppe Coppola, Giuseppe De Placido, Alessandro Conforti, Alviggi, Carlo, Guadagni, R, Conforti, A, Coppola, G, Picarelli, S, De Rosa, P, Vallone, R, Strina, Ida, Pagano, T, Mollo, Antonio, Acampora, A, and DE PLACIDO, Giuseppe

Subjects
Infertility, endocrine system, medicine.medical_treatment, Pilot Projects, Stimulation, Fertilization in Vitro, Poor responders, Andrology, Basal (phylogenetics), Ovarian Follicle, Ovulation Induction, Pregnancy, Risk Factors, FSH, Obstetrics and Gynaecology, medicine, Humans, Sperm Injections, Intracytoplasmic, Ovarian follicle, Chromatography, business.industry, Research, Pregnancy Outcome, Obstetrics and Gynecology, Benzene, medicine.disease, Pollution, Follicular fluid, Follicular Fluid, medicine.anatomical_structure, Oncology, IVF, Population study, Female, Ovulation induction, business
Abstract

Background Several studies have shown that exposure to benzene is associated to menstrual disorders, miscarriages and other disorders of the reproductive system. We performed an observational prospective pilot study to evaluate if levels of benzene in follicular fluid were correlated with response to controlled ovarian stimulation. Method Thirty-four normogonadotrophic women undergoing IVF were enrolled. Intra-follicular benzene levels were evaluated by chromatography/mass spectrometry. Based on median benzene level, we divided the study population in two groups: Group A with a “low” intra-follicular benzene concentration (n = 19, benzene

Full Text
View/download PDF

12. Improving Reporting of Clinical Studies Using the POSEIDON Criteria: POSORT Guidelines.

Author

Esteves SC, Conforti A, Sunkara SK, Carbone L, Picarelli S, Vaiarelli A, Cimadomo D, Rienzi L, Ubaldi FM, Zullo F, Andersen CY, Orvieto R, Humaidan P, and Alviggi C

Subjects
Adult, Female, Humans, Infertility, Female diagnosis, Infertility, Female pathology, Oocytes pathology, Patient-Centered Care methods, Patient-Centered Care standards, Precision Medicine methods, Precision Medicine standards, Pregnancy, Prognosis, Quality Improvement standards, Infertility, Female therapy, Ovarian Reserve physiology, Practice Guidelines as Topic standards, Public Reporting of Healthcare Data, Reproductive Techniques, Assisted standards
Abstract

The POSEIDON ( P atient- O riented S trategies E ncompassing I ndividualize D O ocyte N umber) criteria were developed to help clinicians identify and classify low-prognosis patients undergoing assisted reproductive technology (ART) and provide guidance for possible therapeutic strategies to overcome infertility. Since its introduction, the number of published studies using the POSEIDON criteria has increased steadily. However, a critical analysis of existing evidence indicates inconsistent and incomplete reporting of critical outcomes. Therefore, we developed guidelines to help researchers improve the quality of reporting in studies applying the POSEIDON criteria. We also discuss the advantages of using the POSEIDON criteria in ART clinical studies and elaborate on possible study designs and critical endpoints. Our ultimate goal is to advance the knowledge concerning the clinical use of the POSEIDON criteria to patients, clinicians, and the infertility community., Competing Interests: SE and CA declare receipt of unrestricted research grants from Merck and lecture fees from Merck. SS declares the receipt of honorarium for lectures from Merck, MSD, and Ferring. PH has received unrestricted research grants from MSD, Merck, and Ferring as well as honoraria for lectures from MSD, Merck, Gedeon–Richter, Theramex, and IBSA. CYA has received unrestricted grants from Gedeon-Richter and honoraria for lectures from IBSA, Ferring, and Merck. FU and AV have received honoraria for lectures from MSD and Merck. The funders listed above had no involvement with the study. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 Esteves, Conforti, Sunkara, Carbone, Picarelli, Vaiarelli, Cimadomo, Rienzi, Ubaldi, Zullo, Andersen, Orvieto, Humaidan and Alviggi.)

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results